Azido-PEG1-Val-Cit-OH is a versatile ADC linker with azide functionality and Val-Cit dipeptide for enzymatic cleavage. Ideal for bioorthogonal conjugation and selective payload release in antibody-drug conjugate development.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Azido-PEG1-Val-Cit-OH, a versatile linker compound utilized in bioconjugation and drug delivery systems, finds diverse applications. Here are four key applications:
Antibody-Drug Conjugates (ADCs): Employing Azido-PEG1-Val-Cit-OH as a pivotal linker in ADC synthesis, researchers craft targeted therapies for cancer by merging antibodies with cytotoxic drugs. This sophisticated linker ensures steadfast attachment of the drug to the antibody, enabling controlled release upon binding to the cancer cell target.
Proteomics: Within the realm of proteomics research, Azido-PEG1-Val-Cit-OH serves as a valuable tool for labeling proteins with fluorescent tags or other probes. This labeling strategy enables scrutiny of protein interactions, modifications, and functions within intricate biological systems. The cleavable nature of the linker facilitates the isolation of labeled proteins, paving the way for in-depth analysis and deeper insights into cellular processes.
Site-Specific Bioconjugation: Azido-PEG1-Val-Cit-OH facilitates precise bioconjugation through “click chemistry,” a bio-orthogonal reaction enabling targeted attachment of therapeutic agents, imaging probes, or functional molecules to specific biomolecules. This unparalleled specificity is essential for the development of precision-targeted therapies and advanced diagnostic tools.
Drug Delivery Systems: Fostering innovation in drug delivery systems, Azido-PEG1-Val-Cit-OH plays a pivotal role in designing sophisticated nanoparticles and polymer-drug conjugates. This versatile linker ensures stable drug incorporation within the delivery vehicle, enabling controlled release in response to specific cellular cues. By enhancing drug solubility, bioavailability, and targeted delivery to diseased tissues, this approach revolutionizes drug delivery, promising optimized therapeutic outcomes.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00881 | Azido-PEG3-acid | 1056024-94-2 | |
BADC-00900 | Azido-PEG8-NHS ester | 1204834-00-3 | |
BADC-00901 | Azido-PEG9-amine | 1207714-69-9 | |
BADC-00902 | Azido-PEG8-propionic acid | 1214319-92-2 | |
BADC-00407 | Azido-PEG3-NHS ester | 1245718-89-1 | |
BADC-00911 | Azido-PEG4-propionic acid | 1257063-35-6 | |
BADC-00409 | Azido-PEG2-NHS ester | 1312309-64-0 | |
BADC-00923 | Azido-PEG7-amine | 1333154-77-0 | |
BADC-00404 | Azido-PEG4-PFP ester | 1353012-00-6 | |
BADC-00408 | Azido-PEG2-PFP ester | 1393330-37-4 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.